BioPharmSignal logoBioPharmSignal

Biotech News

Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026

Nkarta (NKTX)NkartaConference / presentation

Two abstracts selected for oral presentations, highlighting investigational CAR-NK cell therapy’s clinical activity in idiopathic inflammatory myopathy and overall safety profile Third abstract selected for poster presentation highlighting NKX019’s clinical activity in systemic sclerosis SOUTH SAN

Related news

NKTXNkarta2026-11-06 21:01 EST

Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026

SNDXSyndax Pharmaceuticals2026-11-04 14:00 EST

Syndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026

ZNTLZentalis2026-10-18 22:05 EST

Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract

BMEABiomea Fusion2026-10-12 20:30 EST

Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist

NKTXNkarta2026-11-05 21:34 EST

Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update

AUTLAutolus Therapeutics plc2026-10-05 12:30 EST

Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026

URGNUroGen Pharma2026-11-03 13:00 EST

UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference

CHRSCoherus BioSciences, Inc.2026-10-14 20:30 EST

Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026

STROSutro Biopharma2026-10-12 12:00 EST

Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference

EXELExelixis2026-11-03 21:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

View all latest news

Nkarta

Allogeneic CAR-NK Company Nkarta develops off-the-shelf natural killer cell therapies for autoimmune disease and cancer. NKX019 NKX019 is a CD19-directed CAR-NK therapy designed to deplete pathogenic B cells without patient-specific manufacturing. Ntrust Studies Ntrust-1 and Ntrust-2 evaluate NKX019 across autoimmune diseases with...

Recent company news

NKTXNkarta2026-11-06 21:01 EST

Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026

NKTXNkarta2026-11-05 21:34 EST

Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update

NKTXNkarta2026-09-10 11:00 EST

Nkarta to Participate in September Investor Conferences

NKTXNkarta2026-09-08 11:00 EST

Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026

NKTXNkarta2026-08-10 20:24 EST

Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights

Stock data

Close
1.57 USD
Market cap
208.2M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States